Aktis Oncology (NASDAQ:AKTS) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Analyst sentiment is broadly positive: Aktis Oncology has a “Moderate Buy” consensus from 11 analysts—nine buy, one strong buy and one sell—with an average 12-month price target of $35.62.
• AKTS shares recently traded at $16.62, well below the average analyst target; the stock has a 12-month range of $13.96 to $34.19.
• Quarterly results missed expectations: Aktis reported a loss of $0.54 per share versus the $0.47 consensus loss, while revenue of $3.91 million also fell short of analysts’ $4.87 million estimate.

Shares of Aktis Oncology (NASDAQ:AKTS - Get Free Report) have received an average rating of "Moderate Buy" from the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $35.62.

Several equities analysts recently issued reports on AKTS shares. BMO Capital Markets started coverage on shares of Aktis Oncology in a research note on Tuesday, August 18th. They set an "outperform" rating and a $37.00 price objective on the stock. Wedbush reaffirmed an "outperform" rating and issued a $35.00 target price on shares of Aktis Oncology in a research note on Friday, October 2nd. Weiss Ratings downgraded Aktis Oncology from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, October 2nd. Oppenheimer assumed coverage on Aktis Oncology in a research note on Wednesday, September 9th. They set an "outperform" rating and a $40.00 price target on the stock. Finally, Wall Street Zen cut Aktis Oncology from a "hold" rating to a "sell" rating in a report on Saturday, July 25th.

Aktis Oncology Trading Up 2.1%

Shares of AKTS stock traded up $0.34 during mid-day trading on Friday, reaching $16.62. The stock had a trading volume of 244,544 shares, compared to its average volume of 347,615. The company has a market cap of $893.33 million and a P/E ratio of -20.27. Aktis Oncology has a 12-month low of $13.96 and a 12-month high of $34.19. The business has a 50-day simple moving average of $18.54 and a 200 day simple moving average of $20.79.

Aktis Oncology (NASDAQ:AKTS - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The technology company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.07). The firm had revenue of $3.91 million for the quarter, compared to analyst estimates of $4.87 million. Research analysts anticipate that Aktis Oncology will post -1.84 EPS for the current year.

Hedge Funds Weigh In On Aktis Oncology

Large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its stake in Aktis Oncology by 8.2% during the third quarter. Russell Investments Group Ltd. now owns 8,391 shares of the technology company's stock worth $163,000 after purchasing an additional 637 shares during the period. State of Wyoming acquired a new position in shares of Aktis Oncology in the 2nd quarter valued at $32,000. The Manufacturers Life Insurance Company grew its stake in shares of Aktis Oncology by 2.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,044 shares of the technology company's stock valued at $1,548,000 after buying an additional 1,051 shares during the period. Global Retirement Partners LLC grew its stake in shares of Aktis Oncology by 289.1% during the 3rd quarter. Global Retirement Partners LLC now owns 1,537 shares of the technology company's stock valued at $30,000 after buying an additional 1,142 shares during the period. Finally, GK Wealth Management LLC acquired a new stake in shares of Aktis Oncology during the 3rd quarter worth $26,000. 28.84% of the stock is currently owned by hedge funds and other institutional investors.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company's pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.